Logo image of HZNP

HORIZON THERAPEUTICS PLC (HZNP) Stock Fundamental Analysis

NASDAQ:HZNP - Nasdaq - IE00BQPVQZ61 - Common Stock - Currency: USD

116.3  +0.05 (+0.04%)

After market: 116.34 +0.04 (+0.03%)

Fundamental Rating

6

HZNP gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. HZNP gets an excellent profitability rating and is at the same time showing great financial health properties. HZNP has a decent growth rate and is not valued too expensively. These ratings could make HZNP a good candidate for quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year HZNP was profitable.
In the past year HZNP had a positive cash flow from operations.
HZNP had positive earnings in 4 of the past 5 years.
HZNP had a positive operating cash flow in each of the past 5 years.
HZNP Yearly Net Income VS EBIT VS OCF VS FCFHZNP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 500M 1B

1.2 Ratios

The Return On Assets of HZNP (4.71%) is better than 95.21% of its industry peers.
With an excellent Return On Equity value of 8.25%, HZNP belongs to the best of the industry, outperforming 95.38% of the companies in the same industry.
The Return On Invested Capital of HZNP (5.35%) is better than 95.87% of its industry peers.
The Average Return On Invested Capital over the past 3 years for HZNP is significantly below the industry average of 14.78%.
Industry RankSector Rank
ROA 4.71%
ROE 8.25%
ROIC 5.35%
ROA(3y)6.1%
ROA(5y)6.05%
ROE(3y)10.47%
ROE(5y)10.88%
ROIC(3y)6.68%
ROIC(5y)4.8%
HZNP Yearly ROA, ROE, ROICHZNP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 20 -20

1.3 Margins

Looking at the Profit Margin, with a value of 12.02%, HZNP belongs to the top of the industry, outperforming 96.04% of the companies in the same industry.
In the last couple of years the Profit Margin of HZNP has declined.
Looking at the Operating Margin, with a value of 15.58%, HZNP belongs to the top of the industry, outperforming 96.53% of the companies in the same industry.
In the last couple of years the Operating Margin of HZNP has grown nicely.
The Gross Margin of HZNP (75.21%) is better than 84.49% of its industry peers.
In the last couple of years the Gross Margin of HZNP has grown nicely.
Industry RankSector Rank
OM 15.58%
PM (TTM) 12.02%
GM 75.21%
OM growth 3Y23.86%
OM growth 5YN/A
PM growth 3Y-31.18%
PM growth 5YN/A
GM growth 3Y1.14%
GM growth 5Y6.97%
HZNP Yearly Profit, Operating, Gross MarginsHZNP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 20 -20 40 60

More info and screens

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so HZNP is destroying value.
Compared to 1 year ago, HZNP has about the same amount of shares outstanding.
The debt/assets ratio for HZNP has been reduced compared to a year ago.
HZNP Yearly Shares OutstandingHZNP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M
HZNP Yearly Total Debt VS Total AssetsHZNP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2B 4B 6B 8B

2.2 Solvency

An Altman-Z score of 5.10 indicates that HZNP is not in any danger for bankruptcy at the moment.
HZNP's Altman-Z score of 5.10 is amongst the best of the industry. HZNP outperforms 81.35% of its industry peers.
The Debt to FCF ratio of HZNP is 2.67, which is a good value as it means it would take HZNP, 2.67 years of fcf income to pay off all of its debts.
HZNP's Debt to FCF ratio of 2.67 is amongst the best of the industry. HZNP outperforms 95.54% of its industry peers.
HZNP has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.48, HZNP is doing worse than 74.92% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 2.67
Altman-Z 5.1
ROIC/WACC0.75
WACC7.16%
HZNP Yearly LT Debt VS Equity VS FCFHZNP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B 4B 5B

2.3 Liquidity

HZNP has a Current Ratio of 4.27. This indicates that HZNP is financially healthy and has no problem in meeting its short term obligations.
HZNP has a Current ratio (4.27) which is comparable to the rest of the industry.
HZNP has a Quick Ratio of 4.09. This indicates that HZNP is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.09, HZNP perfoms like the industry average, outperforming 40.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.27
Quick Ratio 4.09
HZNP Yearly Current Assets VS Current LiabilitesHZNP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B

More info and screens

6

3. Growth

3.1 Past

The earnings per share for HZNP have decreased strongly by -19.39% in the last year.
Measured over the past years, HZNP shows a very strong growth in Earnings Per Share. The EPS has been growing by 33.01% on average per year.
HZNP shows a decrease in Revenue. In the last year, the revenue decreased by -4.42%.
HZNP shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.00% yearly.
EPS 1Y (TTM)-19.39%
EPS 3Y34.76%
EPS 5Y33.01%
EPS Q2Q%12.15%
Revenue 1Y (TTM)-4.42%
Revenue growth 3Y40.8%
Revenue growth 5Y28%
Sales Q2Q%7.82%

3.2 Future

Based on estimates for the next years, HZNP will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.92% on average per year.
HZNP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.94% yearly.
EPS Next Y-5.01%
EPS Next 2Y8.89%
EPS Next 3Y11.9%
EPS Next 5Y15.92%
Revenue Next Year5.55%
Revenue Next 2Y9.53%
Revenue Next 3Y10.34%
Revenue Next 5Y9.94%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
HZNP Yearly Revenue VS EstimatesHZNP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2B 4B 6B
HZNP Yearly EPS VS EstimatesHZNP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 10

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 25.90, HZNP can be considered very expensive at the moment.
Based on the Price/Earnings ratio, HZNP is valued cheaply inside the industry as 95.54% of the companies are valued more expensively.
HZNP's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.35.
The Price/Forward Earnings ratio is 20.14, which indicates a rather expensive current valuation of HZNP.
Compared to the rest of the industry, the Price/Forward Earnings ratio of HZNP indicates a rather cheap valuation: HZNP is cheaper than 96.53% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.19. HZNP is around the same levels.
Industry RankSector Rank
PE 25.9
Fwd PE 20.14
HZNP Price Earnings VS Forward Price EarningsHZNP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, HZNP is valued cheaply inside the industry as 94.88% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HZNP indicates a rather cheap valuation: HZNP is cheaper than 96.37% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 27.79
EV/EBITDA 27.94
HZNP Per share dataHZNP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

The excellent profitability rating of HZNP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.78
EPS Next 2Y8.89%
EPS Next 3Y11.9%

More info and screens

0

5. Dividend

5.1 Amount

HZNP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HORIZON THERAPEUTICS PLC

NASDAQ:HZNP (10/5/2023, 8:25:26 PM)

After market: 116.34 +0.04 (+0.03%)

116.3

+0.05 (+0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2023-08-08/bmo
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners0.58%
Ins Owner Change0%
Market Cap26.63B
Analysts50.91
Price Target118.83 (2.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.7%
Min EPS beat(2)-27.35%
Max EPS beat(2)13.95%
EPS beat(4)3
Avg EPS beat(4)4.23%
Min EPS beat(4)-27.35%
Max EPS beat(4)21.5%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.41%
Min Revenue beat(2)-9.59%
Max Revenue beat(2)6.77%
Revenue beat(4)3
Avg Revenue beat(4)-0.15%
Min Revenue beat(4)-9.59%
Max Revenue beat(4)6.77%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.76%
EPS NY rev (1m)0%
EPS NY rev (3m)-17.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.27%
Valuation
Industry RankSector Rank
PE 25.9
Fwd PE 20.14
P/S 7.31
P/FCF 27.79
P/OCF 25.59
P/B 5.01
P/tB 26.53
EV/EBITDA 27.94
EPS(TTM)4.49
EY3.86%
EPS(NY)5.77
Fwd EY4.97%
FCF(TTM)4.19
FCFY3.6%
OCF(TTM)4.54
OCFY3.91%
SpS15.92
BVpS23.19
TBVpS4.38
PEG (NY)N/A
PEG (5Y)0.78
Profitability
Industry RankSector Rank
ROA 4.71%
ROE 8.25%
ROCE 6.77%
ROIC 5.35%
ROICexc 7.58%
ROICexgc 27.86%
OM 15.58%
PM (TTM) 12.02%
GM 75.21%
FCFM 26.3%
ROA(3y)6.1%
ROA(5y)6.05%
ROE(3y)10.47%
ROE(5y)10.88%
ROIC(3y)6.68%
ROIC(5y)4.8%
ROICexc(3y)9.75%
ROICexc(5y)6.96%
ROICexgc(3y)39.54%
ROICexgc(5y)N/A
ROCE(3y)8.46%
ROCE(5y)6.07%
ROICexcg growth 3Y27.62%
ROICexcg growth 5YN/A
ROICexc growth 3Y33.99%
ROICexc growth 5YN/A
OM growth 3Y23.86%
OM growth 5YN/A
PM growth 3Y-31.18%
PM growth 5YN/A
GM growth 3Y1.14%
GM growth 5Y6.97%
F-Score6
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 2.67
Debt/EBITDA 2.66
Cap/Depr 21.15%
Cap/Sales 2.26%
Interest Coverage 4.07
Cash Conversion 108.78%
Profit Quality 218.81%
Current Ratio 4.27
Quick Ratio 4.09
Altman-Z 5.1
F-Score6
WACC7.16%
ROIC/WACC0.75
Cap/Depr(3y)32.95%
Cap/Depr(5y)21.63%
Cap/Sales(3y)3.95%
Cap/Sales(5y)2.73%
Profit Quality(3y)169.09%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.39%
EPS 3Y34.76%
EPS 5Y33.01%
EPS Q2Q%12.15%
EPS Next Y-5.01%
EPS Next 2Y8.89%
EPS Next 3Y11.9%
EPS Next 5Y15.92%
Revenue 1Y (TTM)-4.42%
Revenue growth 3Y40.8%
Revenue growth 5Y28%
Sales Q2Q%7.82%
Revenue Next Year5.55%
Revenue Next 2Y9.53%
Revenue Next 3Y10.34%
Revenue Next 5Y9.94%
EBIT growth 1Y-37.19%
EBIT growth 3Y74.4%
EBIT growth 5YN/A
EBIT Next Year6.03%
EBIT Next 3Y14.62%
EBIT Next 5Y17.3%
FCF growth 1Y83.52%
FCF growth 3Y42.98%
FCF growth 5Y33.65%
OCF growth 1Y72.19%
OCF growth 3Y43.43%
OCF growth 5Y34.64%